We are continuing our journey to expand the reach and impact of our Immunology portfolio. We began this trajectory more than two decades ago when our scientists pioneered the use of antibodies to tumor necrosis factor (TNF)-alpha to treat chronic, immune-mediated diseases. We build upon our deep expertise and proven track record as we progress our strategy to develop new, promising biologic and oral therapeutics.
Supporting these efforts, our extensive biomarker discovery program compiles valuable information that may ultimately provide healthcare professionals with the tools needed to consistently prescribe the most appropriate treatment to each patient—the first time. Through cutting-edge technologies, our scientists are able to track disease progression and treatment efficacy in pre-clinical studies, providing us with a better understanding of disease mechanisms, longer-term disease impact and the effect of therapy. Computer-based research also offers insight into disease pathogenesis and potential targets for therapeutic intervention, thus accelerating efforts to bring medicines to market.
Our focus on understanding disease at the molecular level is key to the discovery of new targets that drive inflammation and autoimmune processes, and our early work on understanding disease triggers may enable entirely new approaches to treating and potentially preventing disease.